Navigation Links
Blocking the effect of inflammation-causing cells lowered prostate cancer cells invasion

Recent studies have suggested an association between chronic inflammation and cancers of the prostate, colon, stomach and liver. Now scientists at Northwestern University Feinberg School of Medicine report success in blocking an early step in metastasis of prostate cancer cells by interrupting the communication between the cancer cells and other cells that promote inflammation.

Their success suggests new ways to control cancer spread and metastasis. The findings also provide an impetus to look more closely at existing inflammation-controlling drugs including non-steroidal anti-inflammatory drugs, cyclooxygenase inhibitors, antioxidants and statins. It is possible, says Dr. Paul Lindholm, that these widely available drugs could be used to control aggressive cancer cell growth and spread for these and other inflammation-associated cancers.

Dr. Lindholm presented results of the study on April 8 at the Experimental Biology 2008 meeting in San Diego. The presentation was part of the scientific program of the American Society for Investigative Pathology.

In earlier studies, Dr. Lindholm and his colleagues at Northwestern found that when compared to benign prostate tissues, prostate cancer tissue has a higher density of macrophages and the monocytes from which these immune system cells derive. These scavenger cells are vital to the regulation of immune responses and the development of inflammation. High grade and high stage prostate cancer tissues showed significantly increased numbers of macrophages compared to low grade and low stage tumors. When the researchers added monocyte-like cell lines or monocytes obtained from the blood of normal people to less aggressive prostate cancer cell lines, these cancer cells became more invasive, indicating that the cancer cells and the monocytes were indeed communicating with each other. But how?

In the study reported at Experimental Biology, the researchers demonstrated that the monocyte-like cells stimulate the cancer cells Nuclear Factor-kappaB, a gene regulating transcription factor able to stimulate gene activity. To test whether NF-kappaB activity was increasing the cancer cells movement and invasive activity, the researchers then introduced into the cancer cells biological inibitors that blocks NF-kappaB activity. The treatments that block NF-kappaB activity reduced the cancer cell movement and invasion through the basement membrane (a thin, delicate layer of connective tissue underlying the epithelium of many organs).

The researchers now plan to study the effects of macrophages and inflammation and NF-kappaB inhibiting treatments in vivo, in a specially designed mouse model of invasive prostate cancer. They also plan to extend these experiments to include drugs currently used in humans to control inflammation. If anti-inflammatory drugs block cancer cell NF-kappaB activity and spreading movement, as the researchers hope, these drugs may prove useful for patients whose cancers are discovered early but who are at risk for cancer spread. The results also could help identify biomarkers of early cancer, before it can be detected by current technology, and to monitor response to treatments designed to prevent cancer spread.


Contact: Sylvia Wrobel
Federation of American Societies for Experimental Biology

Related medicine news :

1. Blocking protein kills prostate cancer cells, inhibits tumor growth, Jefferson scientists find
2. Blocking Potent Oxidant Could Prevent Morphine Tolerance
3. Dr. William S. Gruss, M.D., Says That Medical Research Shows You Can Reduce Your Risk of Cancer By Up To 77% and Reverse the Effects of Aging in A CARDIOLOGISTS GUIDE TO ... ANTI-AGING, ANTIOXIDANTS & RESVERATROL
4. Disease Management Programs that Focus on Needs of Chronically Ill Patients Can Provide Positive, Cost-Effective Results
5. Journey Lite of Thousand Oaks Announces Special Spring Price Discount In Response to Effects of Softening Economy on Patients Pocketbooks
6. Interview by Internet Can Decrease Greatest End-of-Life Fears: It Facilitates Creating Effective Advance Directives, Living Wills
7. New study finds adverse effects of estrogen replacement therapy are related to the dose
8. Alzheimers vaccine clears plaque but has little effect on learning and memory impairment
9. Study Finds Mass Media Campaigns Alone Can Effectively Reduce High-Risk Sexual Behavior Among Impulsive, Sensation-Seeking Young Adults
10. Nano-sized technology has super-sized effect on tumors
11. Consumer Reports Poll: Most Say TV Drug Ads Should Include Info on How to Report Side Effects
Post Your Comments:
(Date:11/26/2015)... ... ... Jobs in hospital medical laboratories and in the imaging field lead the many ... Medical Group . These fields, as well as travel nursing, ranked at ... through the company’s website, , The leading healthcare staffing agency released ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings ... with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired ... font, giving users limitless opportunities to stylize and create designs quickly and easily, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast ... found on mammography, according to a study published online in the journal Radiology. ... on mammography may necessitate a change in treatment. , Breast MRI is the ...
(Date:11/25/2015)... MN (PRWEB) , ... November 25, 2015 , ... Finnleo, ... through Christmas Eve on several models of traditional and far-infrared saunas. , ... Nordic Spruce is the most traditional Finnish sauna wood, and Finnleo uses only European ...
(Date:11/25/2015)... ... 25, 2015 , ... Dr. John Pierce, Medical Director at the Ageless Forever ... with the Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, the ... the need for surgery, prescription pills, or topical foams. , “Capillus272™ Pro is ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/25/2015)... Calif. , Nov. 25, 2015  Amgen (NASDAQ: ... Biologics License Application (BLA) with the United ... for ABP 501, a biosimilar candidate to Humira ® ... adalimumab biosimilar application submitted to the FDA and represents ... Sean E. Harper , M.D., executive vice ...
(Date:11/25/2015)... 2015 AAIPharma Services Corp./Cambridge Major Laboratories, ... least $15.8  Million to expand its laboratories and ... . The expansion will provide additional office space ... demands of the pharmaceutical and biotechnology markets. ... provide up to 40,000 square feet of expanded ...
Breaking Medicine Technology: